louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03710629: A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes
Official title: A Prospective Observational Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Driver Genes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Non-small Cell Lung Cancer
Keywords: Non-small cell lung cancer, gene mutations
Lead sponsor: The First Affiliated Hospital of Guangzhou Medical University
Sponsor class: OTHER
First posted: 2018-10-18
Enrollment: 750
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The pathologically diagnosed patients with non-small cell lung cancer who were performed with NGS technology

Brief summary: A single-center, non-interventional prospective observational study in the NSCLC patients with different driver genes

Detailed description: The trial was designed as a single-center non-interventional prospective observational study to explore clinical treatments of the NSCLC patients with different driver genes, the impact factors of patient survivals, and the relevance of gene types, clinical treatments, and distribution of gene types. The follow-up visits, interactions between the investigators and patients, patient questionnaires/quality of life, and other patient information will be uploaded via mobile APP, and webchat every three months.

Eligibility criteria: Inclusion Criteria:

* The patients with lung cancer who were performed with next-generation sequencing (NGS) technology from 2015 to 2017;
* The patients who were at least 18 years;
* The pathologically diagnosed patients with non-small cell lung cancer (NSCLC)

Exclusion Criteria:

-None

Primary outcomes:
measure: Differences in overall survival rates
timeFrame: 2018-2022
Secondary outcomes:
measure: Interaction impact between gene types and treatment modalities or regimens on disease-free survivals
timeFrame: 2018-2022
measure: Statuses of clinical treatment regimens
timeFrame: 2018-2022
measure: Relevance of gene types
timeFrame: 2018-2022
measure: Relevance of overall survival rates and gene types
timeFrame: 2018-2022
measure: Impacts of disease-free survivals on gene types
timeFrame: 2018-2022
measure: Impacts of progression-free survivals
timeFrame: 2018-2022
measure: Impact factors of overall survivals
timeFrame: 2018-2022
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Wenhua of Liang
state: Guangdong
Study officials:
affiliation: The First Affiliated Hospital of Guangzhou Medical University
name: Wenhua Liang, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02175329: Clinical Investigation on Zirconia-ceramic Three-unit Bridges With CAD-on Veneering
Official title: A Randomized Clinical Trial of 3-unit Posterior Zirconia-ceramic Fixed Dental Prosthesis (FDPs) Veneered With Layered and Milled (CAD-on) Veneering Ceramics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Three-unit Posterior Bridges
Keywords: CAD/CAM, three-unit posterior bridges, zirconia framework
Lead sponsor: Ivoclar Vivadent AG
Sponsor class: INDUSTRY
First posted: 2014-06-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 60 bridge frameworks are CAD/CAM manufactured from zirconia-ceramic; 30 bridges are veneered with CAD/CAM fabricated lithium disilicate ceramic, 30 bridges are manually layered. The goal is to compare clinical survival , biological or technical behaviour of the restorations.

Detailed description: Randomized prospective controlled clinical study with three-unit posterior bridges made of zirconia-ceramic to compare veneering with manually layering or CAD/CAM fabricated lithium disilicate ceramic veneers. The hypothesis is that there is no difference in clinical survival of the restorations and no difference in biological or technical behaviour.

Eligibility criteria: Inclusion Criteria:

* single missing posterior tooth with two adjacent posterior teeth
* no acute conservative or paradontal treatment need except for the teeth to be treated in the study
* sufficient oral hygiene

Exclusion Criteria:

* known allergies to components
* bruxism
* missing antagonist tooth
* pregnancy or lactation
* missing written consent
* patients which are not expected to be compliant
* severe systemic diseases
* untreated carious lesions
* untreated parodontitis

Primary outcomes:
measure: Number of participants with clinical success
timeFrame: 2 years
Secondary outcomes:
measure: Restoration quality
timeFrame: 1 week, 1 year, 2 years, 3 years, 4 years, 5 years
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Universität Zürich, Zentrum für Zahn-, Mund- und Kieferheilkunde
Study officials:
affiliation: Universität Zürich
name: Andreas Bindl, Dr.med.dent.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02535429: Massage Therapy for HIV-positive People : Effects on Anxiety, Depression, Hyperventilation and Quality of Life
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV-positive Diagnosis
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2015-08-28
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Massage therapy during 1 month and evaluation of depression, hyperventilation, anxiety and quality of life


Eligibility criteria: Inclusion Criteria:

* HIV-positive diagnosis

Exclusion Criteria:

* musculoskeletal disorders

Primary outcomes:
measure: Anxiety measured by Hospital anxiety and depression scale
timeFrame: 5 minutes
measure: Depression measured by Hospital anxiety and depression scale
timeFrame: 5 minutes
measure: Hyperventilation measured by NIJMEGEN questionnaire
timeFrame: 5 minutes
measure: quality of life measured by World Health Organization Quality of Life Questionnaire
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Clinique universitaire Saint-Luc
Study officials:
References:
Clinical trial NCT03249129: Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Official title: Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Bone Marrow Failure
Trauma
Keywords: Trauma
spinal cord
autoimmunity
antibody
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2017-08-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients over 18 years old with spinal cord trauma, for whom CSF sampling may be performed safely within the first 48 hours.

Brief summary: The purpose of the study is to detect the presence of autoantibodies and autoantigens in cerebrospinal fluid early (\<48 hours) following spinal cord trauma.

The study also aims to define the central or peripheral origin of autoantibodies by looking for their simultaneous presence at the blood level and to evaluate the prognostic value of the presence of autoantibodies within the cerebrospinal fluid, as well as on the initial clinical severity than on the recovery potential.


Eligibility criteria: Inclusion Criteria:

1. Patients with spinal cord injury dating back less than 48 hours
2. Men or women over 18 years of age
3. Patients benefiting from social protection
4. Surgery performed within 48 hours of the trauma
5. Informed and signed consent by the patient or trusted person

Exclusion Criteria:

1. Contra-indication to ensure surgical decompression within the first 48 hours following the trauma
2. Coagulation disorders or any condition that may make the lumbar puncture risky (eg, history of lumbar surgery)
3. Severe cranial trauma associated
4. History of autoimmune pathology
5. Immunosuppressive therapy or long-term corticosteroid therapy
6. Patients unable to comply with protocol requirements
7. Person benefiting from legal protection (guardianship / curator)
8. Person deprived of liberty
9. Patient unable to express consent
10. Pregnant women

Primary outcomes:
measure: Level of anti glial fibrillary acid protein antibodies
timeFrame: The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours.
Secondary outcomes:
measure: Blood level of anti glial fibrillary acid protein antibodies
timeFrame: The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours.
measure: Severity of Neurological Impairment
timeFrame: in the initial phase, at day 7, at 1 months, 3 months, 6 months and 1 year
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Lille
name: Fahed Zairi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05000229: Residual Symptoms After Coronavirus Disease (COVID-19) in Lithuanian Population
Official title: Residual Symptoms in Patients With a History of Coronavirus Disease (COVID-19) and Their Impact on Biopsychosocial Functions (Post-Covid Syndrome)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Post-Covid Syndrome
Keywords: Post-Covid syndrome; Rehabilitation
Lead sponsor: Lithuanian University of Health Sciences
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
First posted: 2021-08-11
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The online study will be open to all volunteers over the age of 18 with COVID-19 infection

Brief summary: The aim of the study is to describe the post-covid-19 syndrome in Lithuanian population regarding the remaining symptoms and their impact on physical functioning, work ability and needs of rehabilitation.

Detailed description: Participants with suspected and confirmed cases of COVID-19 infection will complete an anonymous online questionnaire for post-covid syndrome, i.e. symptoms lasting longer than 28 days after post-covid-19 syndrome. The online survey is developed to assess the health state before infection and residual symptoms lasting longer than acute COVID-19 infection, influencing the functional activity and work ability. The needs of rehabilitation will also be assessed.

Eligibility criteria: Inclusion Criteria:

* older than 18 years age patients;
* a history of COVID-19 infection that was and was not positive for SARS-CoV-2 diagnostic or antibody testing
* the duration of remaining symptoms is longer than 28 days
* ability to fulfil internet-based questionnaire

Exclusion Criteria:

* ongoing covid-19 infection
* other comorbidities requiring treatment or rehabilitation

Primary outcomes:
measure: Description of post-covid-19 syndrome in Lithuanian population
timeFrame: 2021.05.04 - 2022.12.31
Secondary outcomes:
measure: Assessment of medical premorbid status in post-covid-19 syndrome
timeFrame: 2021.05.04 - 2022.12.31
Other outcomes:
Locations:
city: Kaunas
country: Lithuania
facility: Lithuanian University of Health Sciences
Study officials:
References:
Clinical trial NCT00213629: myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies
Official title: Transcriptome Analysis Through a Dedicated Macro-array and TcLandscape Repertoire Analysis for Diagnosis of Myositis.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Polymyositis
Dermatomyositis
Keywords: myositis
cDNA arrays
Genes, T-Cell Receptor beta
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
Collaborators: name: Association Française contre les Myopathies (AFM), Paris
First posted: 2005-09-21
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 76
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The diagnosis of the different forms of inflammatory myopathies (polymyositis, dermatomyositis, inclusion-body myositis...) remains difficult which may lead to unappropriate patient care.

Objective 1 : to develop and evaluate the diagnostic value of a dedicated DNA-array (myoARRAY) for adult-onset muscular diseases with focus on inflammatory myopathies.

Objective 2 : to evaluate the diagnostic value of T cell repertoire (TcLand) analysis to distinguish different forms of inflammatory myopathies.


Eligibility criteria: Inclusion Criteria:

* indication of muscle biopsy for diagnostic purpose
* written informed consent

Exclusion Criteria:

* vasculitis
* coagulation disorder, impossibility to perform muscle biopsy

Primary outcomes:
measure: transcriptome
timeFrame: at inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Rouen
country: France
facility: University Hospital of Rouen
state: Seine Maritime
Study officials:
affiliation: University Hospital, Rouen
name: Olivier Boyer, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01106989: Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points
Official title: An Open-label Pilot Study Evaluating Synera® in the Treatment of Patients With Pain Associated With Myofascial Trigger Points
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Myofascial Pain Syndromes
Lead sponsor: ZARS Pharma Inc.
Sponsor class: INDUSTRY
First posted: 2010-04-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.

Detailed description: The purpose of this pilot study is to explore the usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points. The study will consist of a 2-week, open-label treatment period followed by a 2 week follow-up period conducted at a single study site. Eligible patients must have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 identifiable myofascial trigger points. A number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population.

Eligibility criteria: Inclusion Criteria:

* be at least 18 years of age
* have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 myofascial trigger points
* have trigger points confined to the upper back, shoulder, and neck

Exclusion Criteria:

* have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit
* have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit
* have used any injected pain medication with 28 days preceding the Screening/Baseline Visit
* are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.)

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Pain intensity
timeFrame: Two weeks
Secondary outcomes:
measure: Pain interference with activities (eg, general, normal work, sleep)
timeFrame: Two weeks
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: The Center for Clinical Research
state: North Carolina
Study officials:
affiliation: The Center for Clinical Research
name: Richard L Rauck, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05946889: Comparisons of Human Fibrin Glue (Tisseel) Versus Suture and Robotic Versus Traditional Laparoscopy for Ovarian Cystectomy
Official title: Comparisons of Human Fibrin Glue (Tisseel) Versus Suture and Robotic Versus Traditional Laparoscopy for Ovarian Cystectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Women With Ovarian Cyst
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2023-07-14
Enrollment: 88
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who received ovarian cystectomy

Brief summary: Objective: To compare the effects of suture versus human fibrin glue during robotic or laparoscopic ovarian cystectomy

Detailed description: Methods: The medical records of all consecutive women who received robotic or laparoscopic ovarian cystectomy between January 2016 and May 2022 were reviewed. Perioperative outcome and ovarian size were compared.

Expected results: We can get the effects of suture versus human fibrin glue during robotic or laparoscopic ovarian cystectomy. The above information should be important for consultation.

Eligibility criteria: Inclusion Criteria:

* \>20 years old women
* women who received robotic or laparoscopic ovarian cystectomy between January 2016 and May 2022 were reviewed.

Exclusion Criteria:

* Patients who underwent myomectomy at the same time.

Primary outcomes:
measure: Ovarian size
timeFrame: 24 months
Secondary outcomes:
measure: Blood loss
timeFrame: 1 week
Other outcomes:
Locations:
city: Banqiao
country: Taiwan
facility: Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital
state: New Taipei
Study officials:
References:
Clinical trial NCT06734429: Urinary Artificial Sphincter in Children
Official title: Management of Patients Who Had an Artificial Urethral Sphincter by Laparotomy in Childhood
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neurogenic Bladder Disorder
Bladder Dysfunction
Spina Bifida
Urinary Incontinence Due to Urethral Sphincter Incompetence
Child, Only
Keywords: Urinary Artificial Sphincter
Neurogenic Bladder
Child
Outcomes
Retrospective Study
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: Central Hospital, Nancy, France
First posted: 2024-12-16
Enrollment: 15
Sex: ALL
Minimum age (years): 0
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients younger than 18 years old who have neurogenic bladders

Brief summary: Retrospective monocentric study of the outcomes of patients with neurogenic bladder who had a urinary artificial sphincter before the age of 18 years old. Hypothesis: what was the impact of the urinary artificial sphincter on the global management of the patient?

Detailed description: The management of patients with neurogenic bladder is complex. Several patients have been operated multiple times. Surgical procedures such as Mitrofanoff's, bladder neck surgery, bladder augmentation, and urinary artificial sphincter are common. The investigators wanted to analyze the participants' data, which led to the indication of a urinary artificial sphincter and its outcomes.

Eligibility criteria: Inclusion Criteria:

* Patients who were younger than 18 years old when they had an urinary artificial sphincter

Exclusion Criteria:

* Patients who were 18 years old or older when they had an urinary artificial sphincter

Primary outcomes:
measure: Number of participants with urinary sphincter incomptetence
timeFrame: Before surgery
measure: Impact of urinary artificial sphincter on the participants' incontinence
timeFrame: Through study completion, an average of 2 years
Secondary outcomes:
measure: Impact of bladder augmentation on participants' incontinence
timeFrame: Through study completion, an average of 2 years
measure: Impact of Mitrofanoff procedure on participants' incontinence
timeFrame: Through study completion, an average of 2 years
measure: Impact of bladder neck surgery on participants' incontinence
timeFrame: Through study completion, an average of 2 years
measure: Last follow-up
timeFrame: Through study completion, an average of 2 years]
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: University Hospital, Clermont-Ferrand
state: Auvergne
Study officials:
References:
citation: Delgado-Miguel C, Munoz-Serrano A, Amesty V, Rivas S, Lobato R, Martinez-Urrutia MJ, Lopez-Pereira P. Artificial urinary sphincter in congenital neuropathic bladder: Very long-term outcomes. Int J Urol. 2022 Jul;29(7):692-697. doi: 10.1111/iju.14874. Epub 2022 Mar 26.
Clinical trial NCT01435629: A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
Official title: Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Genetic Disorder
Achondroplasia
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2011-09-16
Enrollment: 81
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients enrolled in the GH-1941 study (NCT01516229) expected to achieve the adult height by 2015 and available for follow-up by the investigator

Brief summary: This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).


Eligibility criteria: Inclusion Criteria:

* Patients who were enrolled in the GH-1941 study (1997 to 2006) and expected to theoretically reach the adult height within the study period

Primary outcomes:
measure: To collect change data of adult height (cm) of patients treated with Norditropin® and evaluate the long-term efficacy
timeFrame: At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age
Secondary outcomes:
measure: To monitor the patients to see if they undergo lower limb lengthening
timeFrame: At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References: